November 3, 2026
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million
GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter
Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million
Substantial reduction of expenses and headcount underway, expected to drive at least a 50% reduction in 2027 R&D expenses vs 2025
NOVATO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability.
“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”
Third Quarter 2026 Revenue Highlights and 2026 Revenue Guidance
-
Total revenue in the third quarter 2026 was $173 million. The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches.
-
CRYSVITA revenue in the third quarter 2026 was $109 million, consistent with expected ordering patterns. The company reaffirms its full year 2026 Crysvita revenue guidance of $500 million to $520 million.
-
DOJOLVI revenue in the third quarter 2026 was $30 million. The company reaffirms its full year 2026 Dojolvi revenue guidance of $100 million to $110 million.
-
EVKEEZA® revenue in the third quarter 2026 was $24 million, driven by increased demand from new country launches and early access.
-
MEPSEVII® revenue in the third quarter 2026 was $10 million.
Summary of Third Quarter 2026 Financial Results
| Selected Financial Data (dollars in millions, except per share amounts), (unaudited) | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |
| Total revenues | $ | 173 | | | $ | 160 | | | $ | 523 | | | $ | 466 | |
| Operating expenses: | | | | | | | |
| Cost of sales | | 32 | | | | 28 | | | | 96 | | | | 80 | |
| Research and development | | 154 | | | | 216 | | | | 508 | | | | 547 | |
| Selling, general and administrative | | 97 | | | | 87 | | | | 273 | | | | 261 | |
| Total operating expenses | | 283 | | | | 331 | | | | 877 | | | | 888 | |
| Net loss | $ | (118 | ) | | $ | (180 | ) | | $ | (395 | ) | | $ | (446 | ) |
| Net loss per share, basic and diluted | $ | (1.16 | ) | | $ | (1.81 | ) | | $ | (3.89 | ) | | $ | (4.55 | ) |
Operating Expenses
Total operating expenses for the third quarter 2026 were $283 million, including $34 million of non-cash stock-based compensation.
Net Loss
Net loss for the third quarter 2026 was $118 million, or $1.16 per share basic and diluted, compared with a net loss for the third quarter 2025 of $180 million, or $1.81 per share basic and diluted.
Cash Balance and Net Cash Used in Operations Cash, cash equivalents, and marketable securities were $401 million as of September 30, 2026. For the three months ended September 30, 2026, net cash used in operations was $43 million.
In October 2026, the Company entered into two definitive agreements to sell the PRVs received upon the approval of GENGLYCOS and FAYUVI for a combined price of $413 million. The sale of the GENGLYCOS PRV closed last week and the FAYUVI PRV sale is expected to close later this month. Net proceeds from both sales are expected to be approximately $350 million.
Initiation of substantial expense reductions and reaffirming profitability in 2027
With the recent completion of late-stage development programs, including first-ever FDA approvals in glycogen storage disease type Ia (GSDIa) and Sanfilippo syndrome type A, Ultragenyx is entering a new stage focused on commercial execution and a smaller, more targeted R&D footprint. To support this transition, the company has initiated substantial headcount and expense reductions and expects to reduce 2027 R&D expenses to less than $350 million and 2027 SG&A expenses to less than $375 million. Savings actions include:
-
Reducing headcount by approximately 20%, resulting in a revised workforce of approximately 1,000 employees
-
Completing wind-down of all ongoing studies for GTX-102 for Angelman syndrome
-
Terminating UX701 for Wilson disease based on not achieving study goals
-
Reducing expenses across the company, including reduction of real estate footprint
In addition to executing these critical expense reductions, the company is focused on driving successful launches for GENGLYCOS and FAYUVI and continuing to grow current product revenues. R&D investments will be focused on delivering primary data from the responder endpoint of the ongoing Phase 3 study for DTX301 for ornithine transcarbamylase deficiency, determining if there is a viable path forward for UX143 (setrusumab) for osteogenesis imperfecta, and measured spending to progress early-stage programs for future INDs.
Fourth quarter 2026 financial results are expected to include approximately $25 million of severance and other non-recurring restructuring charges, and the reduction in force is expected to be substantially completed by the end of 2026. The company continues to anticipate achieving full-year GAAP profitability in 2027 and going forward.
Recent Corporate Updates and Upcoming Milestones
-
GENGLYCOS (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa): In August 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval for GENGLYCOS as a treatment for adult and pediatric patients eight years and older with GSDIa. The company received a PRV upon this approval and sold it for $210 million.
-
FAYUVI (rebisufligene etisparvovec) AAV9 gene therapy for the treatment of Sanfilippo syndrome type A (MPS IIIA): In September 2026, the FDA granted standard full approval for FAYUVI as a treatment of pediatric patients with Sanfilippo syndrome Type A. The company received a PRV upon this approval and, in October 2026, entered into a definitive agreement to sell the PRV for $203 million.
-
UX701 (rivunatpagene miziparvovec) AAV9 gene therapy for the treatment of Wilson disease: Additional data in the dose-finding stage of the Cyprus2+ study of UX701 for the treatment of Wilson disease, including data from the fourth dosing cohort, demonstrated clinical activity in some patients, but did not meet the criteria that the majority of patients achieve biochemical response and elimination of standard of care, to advance the program to the pivotal Phase 3, stage of development. UX701 demonstrated a favorable safety profile across all cohorts dosed. Data from the completed study is expected to be presented at an upcoming medical or scientific congress.
The company will terminate further development of this program and is working with clinical sites and patient advocacy groups to support the patient community through this transition.
-
UX016****novel prodrug for sialic acid used as a substrate replacement therapy for the treatment of GNE myopathy: The Phase 1/2 study is evaluating safety and dose of UX016 and its impact on muscle strength in adults with GNEM. The UX016 program is fully funded through clinical proof-of-concept by an external venture philanthropy agreement with a patient group, which supports all costs for the Phase 1/2 study and dosing will be initiated soon.
-
DTX301 (avalotcagene ontaparvovec) AAV8 gene therapy for the treatment of****Ornithine Transcarbamylase, or OTC, deficiency: The Phase 3 Enh3ance placebo-controlled study showed substantial improvement in ammonia control and reduction in the need for scavenger medicines along with profound improvement in global impression scale. The study continues with patients in both treatment and cross-over groups progressing through 64 weeks of follow-up to evaluate the second primary endpoint of the reduction in the use of ammonia scavengers and dietary management. Data are expected in the first half of 2027.
-
UX143 (setrusumab) monoclonal antibody for the treatment of osteogenesis imperfecta: Phase 3 data with pre- and post-hoc analyses were presented at the American Society for Bone and Mineral Research 2026 Annual Meeting showing a meaningful benefit on bone mineral density, fractures, and other endpoints in the two Phase 3 studies. The company will continue to engage regulatory agencies to determine the necessary data to support a regulatory filing and if there is a potential path forward for UX143.
Conference Call and Webcast Information
Ultragenyx will host a conference call today, Tuesday, November 3, 2026, at 2 p.m. PT/5 p.m. ET to discuss the third quarter financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.





July 30, 2026 Culture Powered by Purpose: Celebrating our Emerging Talent In celebration of National Intern Day, Ultragenyx interns and co-ops share how they are contributing across our corporate functions, technical operations, commercial and regulatory teams. Read more >
May 19, 2026 Citizenship One Rare Nation: Ten Years Advancing Our Mission in Europe, Middle East and Africa To mark 10 years of Ultragenyx’s in Europe, Middle East and Africa, we reflect on our steady expansion and our unwavering commitment to reach more people living with rare and ultra-rare diseases around the world. Read more >
April 20, 2026 Citizenship Reflecting on Our Sustainability Journey at Ultragenyx Celebrating Earth Day by reflecting on our sustainability progress and the insights shaping Ultragenyx’s approach to environmental sustainability. Read more >
February 19, 2026 Advocacy When Ordinary Moments Become Extraordinary: Life with Angelman Syndrome One mother’s story of raising a son with Angelman syndrome, navigating uncertainty, finding community, and celebrating everyday moments. Read more >




